乌鸦传媒

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 乌鸦传媒 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 乌鸦传媒, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

ESMO over a photo of a woman wearing a head wrap in a hospital bed looking out the window

<乌鸦传媒>No Luck for Chemo-Free Tx in First-Line Bladder Cancer

Durvalumab alone or with tremelimumab no better than chemotherapy

ESMO over a photo of a woman wearing a head wrap in a hospital bed looking out the window

<乌鸦传媒>Newly Approved Drug Boosts Survival in Metastatic TNBC

Antibody-drug conjugate as third-line option improved survival, response rates

ESMO over a photo of a woman wearing a head wrap in a hospital bed looking out the window

<乌鸦传媒>Another First-Line Combo Succeeds in Advanced RCC

Third immunotherapy plus TKI combination tops sunitinib

A microscope image of ductal carcinoma in situ

<乌鸦传媒>DCIS Tied to Higher Chance of Breast Cancer Death

Black women and those under 40 at particularly high risk

A pile of Belviq and Belviq bottle labels

<乌鸦传媒>A Closer Look at FDA Decision to Pull Lorcaserin

More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision

The blue gloved hand of a surgeon holding a scalpel above an anatomical model of the prostate and bladder

<乌鸦传媒>Surgery Rates Doubled for High-Risk Prostate Cancer

Use of prostatectomy nearly equaled radiotherapy in 2016

risdiplam (Evrysdi) over a photo of a young male in a wheelchair on the beach above FDA APPROVED

<乌鸦传媒>Another ALK Drug Tops Crizotinib in First-Line NSCLC

Ensartinib doubled PFS over older standard, with improved CNS activity

belantamab mafodotin (Blenrep) over a micrograph of multiple myeloma above FDA APPROVED

<乌鸦传媒>FDA OKs Anti-BCMA Drug for Multiple Myeloma

Accelerated approval for belantamab mafodotin after four other therapies

atezolizumab (Tecentriq) over a photo of advanced melanoma above FDA APPROVED

<乌鸦传媒>Triplet OK'd as First-Line Therapy in Melanoma

Immunotherapy plus targeted combo nets FDA approval in BRAF-mutant population

A computer rendering of T cells attacking a cancer cell while coronavirus is moving from the right

<乌鸦传媒>COVID-19 More Deadly Than Cancer Itself?

Highlights from the AACR conference on COVID-19 and cancer

鈥�

22